réalités en rhumatologie # 46_Juin 2012
25
11. TernanT D, aubourg a, MagDelaine-beuzelin
C et al. Infliximab pharmacokinetics in
inflammatory bowel disease patients. Ther
Drug Monit, 2008 ; 30 : 523-529.
12. Xu z, SeiTz K, FaSanMaDe A et al. Population
pharmacokinetics of infliximab in patients
with ankylosing spondylitis. J Clin
Pharmacol, 2008 ; 48 : 681-695.
13. benDTzen K, geboreK P, SvenSon M et al.
Individualized monitoring of drug bioavai-
lability and immunogenicity in rheumatoid
arthritis patients treated with the tumor
necrosis factor alpha inhibitor infliximab.
Arthritis Rheum, 2006 ; 54 : 3 782-3 789.
14. JaMniTSKi a, barTelDS gM, nurMohaMeD MT
et al. The presence or absence of antibo-
dies to infliximab or adalimumab deter-
mines the outcome of switching to etaner-
cept. Ann Rheum Dis ; 70 : 284-288.
15. bongarTz T, SuTTon aJ, SweeTing MJ et al.
Anti-TNF antibody therapy in rheumatoid
arthritis and the risk of serious infections
and malignancies : systematic review
and meta-analysis of rare harmful effects
in randomized controlled trials. JAMA,
2006 ; 295 : 2 275-2 785.
16. baerT F, noMan M, verMeire S et al. Influence
of immunogenicity on the long-term effi-
cacy of infliximab in Crohn's disease. N Engl
J Med, 2003 13 ; 348 : 601-608.
17. Cornillie F, Shealy D, D'haenS G et al.
Infliximab induces potent anti-inflamma-
tory and local immunomodulatory acti-
vity but no systemic immune suppression
in patients with Crohn's disease. Aliment
Pharmacol Ther, 2001 ; 15 : 463-473.
18. MulleMan D, MeriC JC, PainTauD G, et al.
Infliximab concentration monitoring
improves the control of disease activity in
rheumatoid arthritis. Arthritis Res Ther,
2009 ; 11 : R178.
L’auteur a déclaré ne pas avoir de conflits
d’intérêts concernant les données publiées
dans cet article.
03. weiSMan Mh, MorelanD lw, FurST DE et
al. Efficacy, pharmacokinetic, and safety
assessment of adalimumab, a fully human
anti-tumor necrosis factor-alpha monoclonal
antibody, in adults with rheumatoid arthritis
receiving concomitant methotrexate : a pilot
study. Clin Ther, 2003 ; 25 : 1 700-1 721.
04. KeySTone eC, SChiFF Mh, KreMer JM et al.
Once-weekly administration of 50 mg eta-
nercept in patients with active rheumatoid
arthritis : results of a multicenter, rando-
mized, double-blind, placebo-controlled
trial. Arthritis Rheum, 2004 ; 50 : 353-363.
05. wolbinK gJ, voSKuyl ae, leMS WF et
al. Relationship between serum trough
infliximab levels, pretreatment C reac-
tive protein levels, and clinical response
to infliximab treatment in patients with
rheumatoid arthritis. Ann Rheum Dis,
2005 ; 64 : 704-707.
06.
barTelDS gM, wiJbranDTS Ca, nurMohaMeD MT
et al. Clinical response to adalimumab : rela-
tionship to anti-adalimumab antibodies and
serum adalimumab concentrations in rheu-
matoid arthritis. Ann Rheum Dis, 2007 ; 66 :
921-926.
07. lee h, KiMKo hC, rogge M et al. Population
pharmacokinetic and pharmacodynamic
modeling of etanercept using logistic
regression analysis. Clin Pharmacol Ther,
2003 ; 73 : 348-365.
08. rahMan Mu, STruSberg i, geuSenS P et al.
Double-blinded infliximab dose escala-
tion in patients with rheumatoid arthritis.
Ann Rheum Dis, 2007 ; 66 : 1 233-1 238.
09. MulleMan D, Chu Miow lin D, DuCourau E
et al. Trough infliximab concentrations
predict efficacy and sustained control of
disease activity in rheumatoid arthritis.
Ther Drug Monit, 2010 ; 32 : 232-236.
10. wolbinK gJ, viS M, leMS W et al. Development
of antiinfliximab antibodies and relationship
to clinical response in patients with rheu-
matoid arthritis. Arthritis Rheum, 2006 ; 54 :
711-715.
qu’elle soit supérieure en termes de
réponse à la stratégie ne comportant
pas ce suivi pharmacologique. La seule
étude publiée est une étude non compa-
rative sur un faible nombre de patients,
et d’autres travaux doivent encore être
menés [18].
[ Conclusion
Le suivi thérapeutique pharmacologique
des biomédicaments anti-TNFa est per-
tinent dans la PR. Il permet de com-
prendre les principales situations que
le rhumatologue rencontre en pratique :
échec, réponse insuffisante, réaction à
l’injection, échappement secondaire.
L’utilisation en pratique de cet outil de
suivi doit encore être améliorée, en s’ap-
puyant sur de nouvelles études.
Bibliographie
01. ST Clair ew, wagner Cl, FaSanMaDe AA
et al. The relationship of serum inflixi-
mab concentrations to clinical improve-
ment in rheumatoid arthritis : results from
ATTRACT, a multicenter, randomized,
double-blind, placebo-controlled trial.
Arthritis Rheum, 2002 ; 46 : 1 451-1 459.
02. Maini rn, breeDvelD FC, KalDen JR et al.
Therapeutic efficacy of multiple intra-
venous infusions of anti-tumor necrosis
factor alpha monoclonal antibody combi-
ned with low-dose weekly methotrexate
in rheumatoid arthritis. Arthritis Rheum,
1998 ; 41 : 1 552-1 563.